Wall Street Zen Upgrades China SXT Pharmaceuticals (NASDAQ:SXTC) to Sell

China SXT Pharmaceuticals (NASDAQ:SXTC) was upgraded by equities research analysts at Wall Street Zen to a “sell” rating in a research report issued to clients and investors on Saturday.

China SXT Pharmaceuticals Stock Performance

Shares of SXTC stock opened at $3.00 on Friday. The business has a 50-day moving average of $136.56 and a 200 day moving average of $197.70. China SXT Pharmaceuticals has a 1-year low of $2.63 and a 1-year high of $1,176.00.

China SXT Pharmaceuticals (NASDAQ:SXTC) last announced its quarterly earnings results on Wednesday, December 31st. The company reported ($4.50) EPS for the quarter. The business had revenue of $0.31 million during the quarter.

Institutional Investors Weigh In On China SXT Pharmaceuticals

A hedge fund recently raised its stake in China SXT Pharmaceuticals stock. Virtu Financial LLC grew its position in shares of China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) by 107.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 28,983 shares of the company’s stock after acquiring an additional 15,013 shares during the period. Virtu Financial LLC’s holdings in China SXT Pharmaceuticals were worth $46,000 as of its most recent SEC filing. 5.02% of the stock is owned by institutional investors and hedge funds.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.